Study supports broader indication for Lymphoseek

04/4/2013 | Reuters · RTT News

Interim analysis of a Phase III trial showed that Navidea Biopharmaceuticals' imaging agent Lymphoseek was able to accurately detect cancerous lymph nodes in 38 of 39 patients with head and neck cancer. Use of the agent allowed for the removal of fewer lymph nodes -- an average of four per patient, compared with 38 under standard care. In light of the findings, a safety monitoring committee has advised that the trial be halted early, the company said. Navidea is planning to seek approval of the expanded use of the agent later this year. Lymphoseek was approved last month for lymphatic mapping in people who have breast cancer or melanoma.

View Full Article in:

Reuters · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX